Seeking Alpha
23 Nov 2025, 10:36 UTC · 43w ago
Verdict
Headline takes no side. We score PHVS +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Pharvaris expects pivotal phase 3 data for its HAE treatment pipeline by year-end 2025.
So whatPhase 3 clinical results are the primary catalysts for biotech valuation and regulatory approval potential.
More positive than 92% of claims this week
The author assigns a 90%+ probability of success to the upcoming phase 3 readout for Deucrictibant based on phase 2 results and regulatory precedent.
So whatHigh estimated probability of success lowers the perceived risk premium for investors.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 76% of claims this week
Pharvaris is initiating a buy rating with a $40 target price based on its differentiated oral bradykinin B2 antagonist franchise.
So whatAnalyst price targets provide a sentiment signal but carry less weight than the underlying clinical data.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Initiated with a buy rating and high probability of success for late-stage pipeline data.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+45.1%
Price agrees with the score
$36.02 vs $24.83 close before publication (Nov 21) · not market-adjusted
PHVS chart →